Updates

Innovaderma - Broker calls up shares to 600p

July 2017

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Innovaderma touched £4 this month, becoming the second of our 10 new year recommendations to double (the other being Warpaint). This followed news that trading continues to be strong with May achieving the highest-ever monthly revenue and as SCSW foreshadowed last month, Innovaderma has said profits for the full year to 30 June 2017 will be “well ahead of expectations.” Hybridian now forecasts £1.2m pretax profit (eps 7.7p) for the year ended June, with £2.56m (14.5p) forecast for this year. Even that could be light as it assumes just a 10pc increase on the H2 run rate. They’re talking the shares up to £6. I think it’s run ahead of itself a little for the moment. ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Kalibrate

Wincanton - Cheaper than new issue Eddie Stobart

InnovaDerma (October 2018)

InnovaDerma (June 2018)

InnovaDerma - Soon-to-be prospective PE of 10.6 (March 2018)

Innovaderma - Shares look unduly depressed (December 2017)

Innovaderma (November 2017)

Innovaderma (October 2017)

Innovaderma (June 2017)

Innovaderma - All time record quarter (May 2017)

Innovaderma - Beauty of the internet age (March 2017)

Innovaderma (February 2017)

Innovaderma - An enigma (January 2017)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X